Creatine Monohydrate

Verdict: Probable (for sarcopenia / functional capacity / cognition in older adults) / Suggestive (for any direct lifespan claim) Last reviewed: 2026-04-24 Triangulated against anchor: Resistance training (Strong) — creatine is an adjunct to it

TL;DR

Creatine monohydrate is the best-evidenced supplement in sports nutrition. The aging-relevant case (sarcopenia mitigation, modest cognitive benefit in older adults, especially when paired with resistance training) is Probable. The broader "creatine is a longevity drug" framing extends beyond what the evidence supports — there is no mortality data and no direct lifespan trial. Probable as a high-leverage adjunct to resistance training, Suggestive as a standalone longevity intervention.

What it is

A nitrogenous organic acid; endogenously synthesized from arginine, glycine, and methionine; concentrated in muscle and brain as phosphocreatine, the rapid-energy buffer for short-burst ATP demands. Supplementation increases tissue creatine stores by 10-40%. Standard dosing: 3-5 g/day; loading protocols 20 g/day for 5-7 days then 3-5 g/day. Creatine monohydrate is the most-studied form; alternative forms (HCl, ethyl ester) lack additional benefit.

Proposed mechanism

• Increased phosphocreatine pools → improved ATP regeneration in high-demand tissues (muscle, brain)
• Enhanced training adaptation when combined with resistance exercise — strength, hypertrophy, work capacity
• Cognitive support — particularly in conditions where cellular energy demand is elevated relative to supply (sleep deprivation, aging brain, vegetarian baseline)
• Possible neuroprotective effects via energy buffering and antioxidant action

Confidence: Established for the energy-buffering mechanism and resistance-training synergy.

Evidence ladder

Animal models (T3-T4)

Creatine extensively studied in models of neurodegeneration (Huntington, Parkinson, ALS) — mixed-positive on disease-specific endpoints; lifespan effects not central in animal aging research.

Human (T1)

The strongest evidence is in the resistance-training and cognitive-aging contexts.

Sarcopenia / functional capacity:

• Multiple meta-analyses of creatine + resistance training in older adults: significantly larger gains in lean mass, strength, functional outcomes vs RT alone.
• Effects most pronounced in older adults; lower-magnitude or absent in young trained populations (where baseline creatine stores are higher and training response is already large).

Cognition:

• Systematic review 2025 (PubMed 40971619, PMC12793482, Nutrition Reviews 2025) — 16 RCTs, 492 participants. Memory benefit is driven by older adults (66-76 years). Effect sizes are modest but consistent.
• 2024 meta-analysis (PMC11275561) — creatine supplementation improved memory in older adults; cognitive benefits were modest in young adults.
• Mechanistic plausibility: aging brain has lower energy reserves; creatine restoration plausibly buffers cognitive demand.
• Trial in MCI ongoing (NCT06948149).

Mortality / lifespan endpoint:

• No direct mortality RCT.
• Indirect inference: creatine improves resistance-training outcomes, resistance training improves mortality, therefore creatine plausibly contributes — but this is mechanism-level inference, not direct evidence.

Population caveats

Effects are larger and more reliable in:

• Older adults (vs younger)
• Vegetarians/vegans (lower baseline creatine stores)
• Women (sometimes; data heterogeneous)
• Resistance-trained populations (synergy with training)

Confounds

• Baseline creatine stores — meat-eating young men have high baseline; effect ceiling is lower. Vegetarians and older adults have headroom.
• Combined with exercise — most aging-relevant evidence uses creatine plus resistance training; isolating creatine's standalone contribution is hard.
• Adherence and dosing — 3-5 g/day is small and easy; compliance generally high.
• Water retention is a known short-term effect; not problematic but may confound early body-composition measurements.

Conflict of interest scan

• Some industry support exists (sports nutrition), but creatine monohydrate is generic and cheap; the major evidence base is academic / sports-medicine independent.
• ISSN (International Society of Sports Nutrition) position stand summarizes consensus; modest discount on advocacy framing, but the underlying RCT evidence is robust.
• No major discount applied.

Human translation

Honest decomposition:

1. For older adults doing resistance training: creatine is one of the most evidence-supported supplements. The marginal benefit on strength, lean mass, and cognition is real and clinically meaningful. Probable verdict.
2. For older adults not doing resistance training: standalone creatine has modest cognitive evidence (memory) and weaker functional evidence. Suggestive-to-Probable depending on framing.
3. For young, healthy, meat-eating, well-trained adults: creatine improves training outcomes; "longevity" framing is mechanism-level inference rather than direct evidence.
4. As a standalone aging drug: no mortality data exists. The longevity case rests on its synergy with resistance training plus modest cognitive evidence.

Calibrated verdict

Probable for the well-defined use cases (sarcopenia mitigation in older adults, especially with resistance training; modest cognitive benefit in older adults). Suggestive for the broader "creatine extends lifespan" framing.

Compared to resistance training (Strong), creatine is an adjunct that amplifies a Strong intervention's effects in older populations. It cannot inherit RT's verdict on its own.

Compared to rapamycin (Probable), creatine has better hard-endpoint human evidence on functional outcomes (gait, strength, falls) and less of a mouse-lifespan story. They sit at the same band for opposite reasons.

Compared to NMN (Suggestive), creatine has substantially better human RCT evidence and stronger mechanistic foundation; creatine sits one band above.

Confidence interval on verdict

• Could move to Strong (in older adults / sarcopenia context) with very large pre-registered RCTs on hard functional endpoints — modest probability within 2 years.
• Could move to Suggestive (overall) only if a major safety signal emerged; none currently apparent.
• Most likely 2-year trajectory: stable at Probable; further consolidation of cognitive-benefit evidence in older adults.

Open questions

• Q: For lean active older adults already doing resistance training, what is the marginal benefit of adding creatine vs simply increasing protein intake?
• Q: How much of the cognitive benefit is mediated through improved exercise adherence (more energy → train more → indirect benefit) vs direct neurometabolic effects?
• Q: Is the apparent female responsiveness to creatine for muscle/cognition real and underutilized, or measurement artifact?
• Q: Long-term safety beyond 5 years — extensively studied but rare-event monitoring is limited.

Sources

• Creatine and Cognition in Aging: Systematic Review (PubMed 40971619, Nutrition Reviews 2025)
• Creatine and cognition systematic review and meta-analysis (PMC11275561)
• Frontiers Physiol 2024 — Creatine plus RT for healthy aging
• Creatine for older adults and clinical populations, J Int Soc Sports Nutr 2025
• Impact of creatine supplementation and exercise training (PMC12506341)
• Cognitive Vitality creatine review (Alzheimer's Drug Discovery Foundation)
• NCT06948149 — Creatine and Resistance Training in Older Adults With MCI

Produced under methodology locked 2026-04-24. Triangulated against resistance-training context.